DEC 1 9 2002 DOCKET NO. 219148US0CONT

BEST AVAILABLE COPYRECEIVED

DEC 2 3 2002

K OFFICE 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

:EXAMINER: MARVICH

Thomas RITTER, et al.

SERIAL NO.: 10/068,916

:ART UNIT: 1636

FILED: February 11, 2002

FOR: GENETICALLY MODIFIED T-CELLS, METHOD FOR PRODUCING THEM

AND USE THEREOF

AMENDMENT AND REQUEST FOR RECONSIDERATION

HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, D.C. 20231

SIR:

In response to the Official Action mailed July 19, 2002, Applicants request reconsideration in light of the following amendments and remarks.

IN THE SPECIFICATION

Please amend the specification as follows:

Page 1, at line 5, please insert the following:

(D)

--CROSS-REFERENCE TO A RELATED APPLICATION

The present application is a Continuation of PCT/DE01/02184 filed June 8, 2001.--

IN THE CLAIMS

Please cancel Claims 1-17 and add the following new claims:

18. (New) An *in vitro* modified T cell, obtained by stimulating a T cell of a graft recipient *in vitro* with a cell of a graft donor or with a cell that expresses a dominant MHC molecule to yield a graft recipient-specific T cell; and transfecting the graft recipient-specific T cell with a therapeutic gene.